B-vitamins may delay Alzheimer’s onset


UK researchers have found that high doses of B-vitamins – including folic acid, vitamin B12 and vitamin B6 – can slow down brain tissue atrophy, a wasting process associated with Alzheimer’s disease.

David Smith of the University of Oxford, and colleagues, used randomised controlled trials to test the long-term effects of B-vitamins on the brain health of elderly people with mild cognitive impairment, who were classed as having an increased risk of dementia. They found the brains of those treated with B-vitamins shrank less over a two year period than those given a placebo, and experienced less atrophy in regions of grey matter especially vulnerable to Alzheimer’s.

They also showed that the supplements effectively reduced blood concentrations of homocysteine, high levels of which have been linked to Alzheimer’s and cognitive impairment.

The work suggests addressing non-genetic aspects of Alzheimer’s may identify better treatment options. Alzheimer’s is the most common cause of dementia, with over 25 million sufferers worldwide. Several potential treatments have failed in recent clinical trials.


Related Content

Renewed focus on dementia checked by drug challenges

3 July 2014 News and Analysis

news image

'Ticking time bomb' of global neurodegenerative disease burden will be difficult to defuse

Zinc ruled out as biomarker for Alzheimer’s disease

31 March 2014 Research

news image

Study says decreasing serum zinc levels are a sign of ageing

Most Read

Sun rises on new solar route to hydrogen

27 February 2015 Research

news image

Photocatalyst has solar-to-hydrogen conversion efficiency of 2% and points way to cheap production of the gas

The mothers of invention

24 February 2015 Managing Change

news image

Nina Notman profiles four researchers successfully balancing an academic career with family life

Most Commented

Sun rises on new solar route to hydrogen

27 February 2015 Research

news image

Photocatalyst has solar-to-hydrogen conversion efficiency of 2% and points way to cheap production of the gas

Hepatitis C drug patent challenged in Europe

19 February 2015 Business

news image

Campaign group says Gilead’s expensive blockbuster sofosbuvir is not innovative enough to warrant a patent